fb icon

Podcast EP #118 | Testosterone and Depression: The Hormone Panel Nobody Ran

He was 28 and had carried a diagnosis of major depressive disorder since late high school. Over about ten years he moved from his pediatrician to primary care to psych, and through four or five antidepressants. Some helped a little. By the time he sat down in Nico Misleh’s office, he was apathetic, his libido was gone, and he had gained about 30 pounds. He could not remember a time he had not felt depressed.

In Episode 118 of the HRT University Podcast, Nico Misleh, MSN, FNP-C, tells the story of that patient. He uses it to ask what guideline-concordant care can miss, and why the answer in this case came from a hormone panel.

Can low testosterone cause depression?

Low testosterone and depression share symptoms, and this patient had them: apathy, low motivation, low libido and weight gain. A 2019 meta-analysis in JAMA Psychiatry pooled 27 randomized placebo-controlled trials with 1,890 men. It linked testosterone treatment to a reduction in depressive symptoms. The authors noted that most trials had a high or unclear risk of bias. Many of the men studied were hypogonadal without a depression diagnosis. They called for trials that measure depression as the primary outcome.

What did ten years of guideline care look like?

Nico says almost any provider would read that chart the same way. The chart showed ten years of major depressive disorder and several SSRIs that did not do enough. The usual next step would be another SSRI or an add-on such as bupropion. He would also get a different medicine for erectile dysfunction and a follow-up in a few months. That plan matches the guidelines. It had also produced the same patient for a decade.

Nico is clear that he is not criticizing psych providers. He has prescribed SSRIs himself and believes they have a time and place. His episode speaks to providers who follow the guidelines exactly, watch a patient fail to improve, and suspect something is missing.

Why is a PHQ-9 score not an objective test?

The PHQ-9 is a self-administered questionnaire that scores each of the nine DSM-IV criteria for depression from 0 to 3. Nico’s patient would have scored high on it. Nico compares it to a 1-to-10 pain scale: the number helps guide care, and it still measures how a person feels. It does not tell you what is causing the symptoms.

Nico did not doubt the depression. He saw the depression as a syndrome, several factors stacked on top of each other, and went looking for what sat underneath it.

What did the hormone panel show?

Nico checked vitamin B12, vitamin D, iron and testosterone. Vitamin D came back on the low side. Total testosterone came back at about 320, at the low end of the reference range. Free testosterone came back at about 7, with the low end of his lab’s range at 6.

By those numbers the patient did not meet the diagnostic threshold for hypogonadism. In Nico’s view, that threshold reflects population statistics more than the physiology of the person in front of you. This patient had the symptoms of low testosterone.

What happened after treatment?

Nico prescribed injectable testosterone off label. He was treating the depressive symptoms based on the patient’s physiology and presentation, without relying on a lab cutoff.

Six weeks later the patient said it was the first time in his life he had felt like his whole self. He had started exercising for the first time, his energy lasted all day, and his brain fog was gone. His libido and erectile function returned, and he no longer needed medicine for erectile dysfunction. His girlfriend, now his wife, came to that appointment to thank Nico. The patient also told him the last ten years had felt like a waste.

“I ran a hormone panel. That was it,” Nico says. He is just as clear that testosterone is not the answer for every man with depression. Cases do not always turn out this way.

What does off-label prescribing mean?

The FDA describes off-label use as the unapproved use of an approved drug. Once the FDA approves a drug, providers generally may prescribe it for an unapproved use when they judge it medically appropriate for their patient. The FDA has not determined that the drug is safe and effective for that use.

Off-label prescribing is common. A 2006 study in Archives of Internal Medicine found that about 21% of office-based prescriptions in 2001 were off label. Of those, 73% had little or no scientific support. Nico calls off-label a regulatory term. It describes what the FDA reviewed, and the clinical case still has to stand on its own.

How do you document off-label care?

Nico’s view is that guideline concordance alone does not protect a provider. Clinical reasoning that you can show does. The chart should start with a thorough evaluation and a physiological basis built on both subjective and objective data. Informed consent, a clear monitoring plan and a note that the use is off label complete it. He adds that he is not giving legal advice.

He also argues that the larger risk often runs the other way. Nobody looks, and a cause goes missed for ten years. Or fear keeps a provider from an appropriate off-label option.

Is guideline-concordant care the same as clinical reasoning?

Nico respects guidelines. They set population defaults, give providers legal footing and offer a place to start. They also sit downstream of the studies behind them, so the people those studies enrolled and the groups that paid for them shape the result. The average patient in a study may not be the patient across from you.

“Guideline concordance is not the same as clinical reasoning,” Nico says. He sees the difference as a training outcome. When a provider understands the physiology well enough, the guideline works as the floor of a decision. Nico applies the same question to women in their 50s going through menopause who report symptoms of depression.

Listen to Episode 118

Hear the full conversation in Episode 118 of the HRT University Podcast on Spotify, Apple Podcasts and YouTube. Episode 96 covers hormones and depression. Our guide to free testosterone and SHBG covers what total testosterone misses. Episode 115 covers why principles beat protocols in clinical reasoning.

Frequently asked questions

Can low testosterone cause depression?

They share symptoms such as apathy and low libido. A 2019 meta-analysis of 27 randomized trials with 1,890 men linked testosterone treatment to a reduction in depressive symptoms. Most of the trials had a high or unclear risk of bias, and the authors called for trials with depression as the primary outcome.

Can testosterone be prescribed off label for depression?

The FDA says providers generally may prescribe an approved drug for an unapproved use when they judge it medically appropriate for their patient. When he does, Nico documents his clinical reasoning along with informed consent and a monitoring plan. Rules vary by state and license, so check yours.

What does off-label mean?

Off-label means using an approved drug for a use, dose or form the FDA has not approved. It describes the regulatory review and says nothing on its own about whether a choice is clinically sound.

Is the PHQ-9 a diagnostic test?

The PHQ-9 is a self-administered nine-item questionnaire based on the DSM-IV criteria for depression. Nico treats it as a measure of how a patient feels, which still leaves the cause to find.

Should every man with depression get testosterone?

No. Nico says so directly in the episode. Depression has many possible contributors, and a hormone panel is one part of the workup.

Learn the physiology behind the decision

Cases like this one turn on reading a hormone panel through physiology. The HRT University Master Course teaches physiology-first hormone therapy for men and women. It covers six clinical modules and 30 CE hours, 12 of them in pharmacology. Explore the Master Course.

References

  1. Walther A, Breidenstein J, Miller R. Association of testosterone treatment with alleviation of depressive symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry. 2019;76(1):31-40. https://pmc.ncbi.nlm.nih.gov/articles/PMC6583468
  2. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606-613. https://pubmed.ncbi.nlm.nih.gov/11556941/
  3. U.S. Food and Drug Administration. Understanding unapproved use of approved drugs “off label.” https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
  4. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Archives of Internal Medicine. 2006. Summary: https://geiselmed.dartmouth.edu/news/2006_h1/08may2006_radley.shtml

Continue Reading

Board-certified FNP. Treating hormone patients since 2018. Built the clinical education program that licensed providers now use.

In This Article

Master Course

Add hormone services to your practice with confidence.

The clinical framework, the lab interpretation, and the case experience. Everything you need to treat hormone patients and know why.

30 CEs

6 Modules

Jointly Accredited

12,000+ Graduates

Keep reading

One clinical insight per week.

The physiology that changes how you practice. No hype. No spam. Just the cases and questions most courses skip.

Go Deeper

The Master Course

Six modules. Thirty CEs. Jointly accredited. The physiological framework that holds when the guidelines do not.